27 Drydock Avenue
8th Floor
Boston, MA 02210
United States
877 422 5362
https://www.ginkgobioworks.com
版塊: Healthcare
行業: Biotechnology
全職員工: 1,218
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Mr. Mark E. Dmytruk | Chief Financial Officer | 465.25k | 無 | 1972 |
Mr. Thomas Knight Jr. | Founder | 無 | 無 | 無 |
Mr. Austin Che Ph.D. | Founder, Head of Strategy & Treasurer | 無 | 無 | 無 |
Mr. Bartholomew Canton | Founder, CTO & Secretary | 無 | 無 | 無 |
Mr. Steven P. Coen CPA | Chief Accounting Officer | 無 | 無 | 無 |
Karen Tepichin | General Counsel & Secretary | 無 | 無 | 無 |
Ms. Anna Marie Wagner | Senior Vice President of Corporate Development | 無 | 無 | 無 |
Ms. Samantha Sutton | Head of People | 無 | 無 | 無 |
Mr. Joshua Dunn | Head of Design | 無 | 無 | 無 |
Mr. Joaquim Marques | Head of Omics & Analytical Chemistry | 無 | 無 | 無 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
截至 2024年5月1日 止,Ginkgo Bioworks Holdings, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中:9;董事會:6;股東權利:10;現金賠償:9。